Characteristics of Patients with Psoriasis Treated with Apremilast in the Corrona Psoriasis Registry

[1]  B. Strober,et al.  Utilization of the validated Psoriasis Epidemiology Screening Tool to identify signs and symptoms of psoriatic arthritis among those with psoriasis: a cross‐sectional analysis from the US‐based Corrona Psoriasis Registry , 2019, Journal of the European Academy of Dermatology and Venereology : JEADV.

[2]  J. Soung,et al.  Treating moderate plaque psoriasis: prospective 6-month chart review of patients treated with apremilast , 2018, The Journal of dermatological treatment.

[3]  M. Lebwohl,et al.  Combination Use of Systemic Therapies in Psoriasis: Baseline Characteristics from the Corrona Psoriasis Registry , 2018, Journal of drugs in dermatology : JDD.

[4]  A. Egeberg,et al.  Adverse events associated with apremilast use and withdrawal for psoriasis in a real‐world setting , 2018, Journal of the European Academy of Dermatology and Venereology : JEADV.

[5]  D. Rigopoulos,et al.  Real‐world data on the efficacy and safety of apremilast in patients with moderate‐to‐severe plaque psoriasis , 2018, Journal of the European Academy of Dermatology and Venereology : JEADV.

[6]  B. Strober,et al.  Characterization of disease burden, comorbidities, and treatment use in a large, US‐based cohort: Results from the Corrona Psoriasis Registry , 2018, Journal of the American Academy of Dermatology.

[7]  A. Armstrong,et al.  Real-World Clinical Experience With Apremilast in a Large US Retrospective Cohort Study of Patients With Moderate to Severe Plaque Psoriasis. , 2017, Journal of drugs in dermatology : JDD.

[8]  J. Soung,et al.  Defining and Treating Moderate Plaque Psoriasis in a Real-World Clinical Setting: A Dermatologist Survey and Prospective 6-Month Chart Review of Patients Treated with Apremilast , 2017 .

[9]  B. Strober,et al.  Efficacy and Safety of Apremilast in Patients With Moderate Plaque Psoriasis With Lower BSA: Week 16 Results from the UNVEIL Study. , 2017, Journal of drugs in dermatology : JDD.

[10]  M. Gooderham,et al.  The efficacy and safety of apremilast, etanercept and placebo in patients with moderate‐to‐severe plaque psoriasis: 52‐week results from a phase IIIb, randomized, placebo‐controlled trial (LIBERATE) , 2016, Journal of the European Academy of Dermatology and Venereology : JEADV.

[11]  G. Girolomoni,et al.  Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with moderate‐to‐severe plaque psoriasis over 52 weeks: a phase III, randomized controlled trial (ESTEEM 2) , 2015, The British journal of dermatology.

[12]  S. Chimenti,et al.  Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: Results of a phase III, randomized, controlled trial (Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis [ESTEEM] 1). , 2015, Journal of the American Academy of Dermatology.

[13]  M. Lebwohl,et al.  Patient perspectives in the management of psoriasis: results from the population-based Multinational Assessment of Psoriasis and Psoriatic Arthritis Survey. , 2014, Journal of the American Academy of Dermatology.

[14]  P. Helliwell,et al.  Evaluation of an existing screening tool for psoriatic arthritis in people with psoriasis and the development of a new instrument: the Psoriasis Epidemiology Screening Tool (PEST) questionnaire. , 2009, Clinical and experimental rheumatology.